Please login to the form below
chemotherapy
This page shows the latest chemotherapy news and features for those working in and with pharma, biotech and healthcare.
First-line ovarian approval cements AZ’s Lynparza lead
The new FDA approval means that Lynparza (olaparib) can be given to patients who are in complete or partial response to first-line treatment with platinum-based chemotherapy for ovarian, fallopian ... The study showed Lynparza achieved a
Latest news
-
AZ still sees route to approval for Imfinzi in MYSTIC trial
more pronounced after two years’ follow-up, at 38.3% for monotherapy versus 22.7% for standard-of-care chemotherapy. ... chemotherapy. AZ can in some respects afford to gamble a little more of its R&D budget on Imfinzi and tremelimumab as Imfinzi is
-
CAR-Ts take centre stage as ASH18 comes to a close
Among 17 patients who received a lymphodepletion regimen of the chemotherapy agents fludarabine and cyclophosphamide with Allogene’s anti-CD52 antibody ALLO-647, designed to give the CAR-T cells space
-
Dutch biotech Argenx claims $1.8bn licensing deal with J&J
Cusatuzumab is currently in a clinical trial in newly-diagnosed elderly patients with AML and MDS patients who aren’t able to be treated with chemotherapy.
-
GSK buys cancer firm Tesaro for $5.1bn
Zejula is approved in the US and Europe for recurrent ovarian cancer patients in response to platinum-based chemotherapy, with and without BRCA mutations, and made $63m in sales in the
-
ASH18: CAR-T and drugs give new options for multiple myeloma
J&J also reported new trial results for Darzalex in newly-diagnosed myeloma patients, showing in the ALCYONE trial that adding the drug to chemotherapy in patients ineligible for HSCT reduced
More from news
Approximately 6 fully matching, plus 755 partially matching documents found.
Latest Intelligence
-
Is China ready for a pharmaceutical gold rush?
Earlier this year, data showed Keytruda combined with chemotherapy could cut the risk of death among previously untreated lung cancer patients by 51%.
-
AstraZeneca’s oncology renaissance
that has not spread widely around the body after platinum chemotherapy or radiotherapy. ... However, recent overall survival results from the MYSTIC trial, which studied Imfinzi with CTLA4 inhibitor tremelimumab, have just confirmed the combination
-
Cancer immunotherapy: What's on the horizon?
Last year, the FDA approved Merck’s Keytruda (pembrolizumab) as a first-line agent alongside chemotherapy for metastatic NSCLC on data showing the chance of cancer progression was cut in half. ... Opdivo after standard treatment of early-stage lung
-
The threat of antimicrobial resistance
After all, so many of today’s life-saving healthcare advances, from cancer chemotherapy to heart surgery, rely on effective antibiotics being available to prevent infections in patients.
-
Taking a lean and careful approach
Chemotherapy and Pharmacology, which concluded its treatment regimen showed ‘encouraging clinical benefit’.
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
Latest appointments
-
Dr Sotirios Stergiopoulos leaves Shire for Ipsen
affairs strategies and a strong expertise in oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumour indications.
-
BMS appoints oncology development head
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
-
AP Pharma overhauls senior management team
AP Pharma's lead product APF530 for the prevention of chemotherapy-induced nausea and vomiting.
-
AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales
Joins as company prepares to advance APF350 to treat side effects of chemotherapy. ... The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended for the prevention of acute- and delayed-onset chemotherapy-induced
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
Will lead launch of drug to prevent chemotherapy-induced nausea. AP Pharma has appointed the former global head of oncology at Bayer Healthcare Robert Rosen as its new senior VP and ... In this role he will lead efforts at the US-based specialty pharma
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Innovation in pharma: the highs and lows of the current healthcare economy
Also in cancers: chimeric antigen receptor T cell (CAR-T) therapy, a type of cancer immunology that could dismiss chemotherapy in some cancers, is now licensed in the US. .
-
CASE STUDY: Creation of Global Value Dossiers for a US-based Global Pharmaceutical Company
Febrile Neutropenia (FN) during adjuvant chemotherapy is associated with significant morbidity, mortality risk, and incremental costs. ... The client wanted a vendor to develop content for a Global Value Dossier (GVD) about the burden of febrile
-
How pembrolizumab will change the management of advanced lung cancer
The Phase III KEYNOTE-024 trial assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1)
-
Products as portfolios: positioning immuno-oncology products
These changes, in turn, are having a fundamental impact on approaches to treatment and standards of care in the same way that surgery, radiotherapy, and chemotherapy have done in the past.
-
Immunotherapy in oncology
This is very different to how we currently assess chemotherapies – by their response rates – where stable disease would be perceived as a poor response.
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
Featured jobs
-
Medical Writer
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
-
Senior Account Manager
-
Competitive Salary Offered
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
-
Account Manager / Account Director
-
Competative
- Global Business Development Director – Health Education
-
excellent commission
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
